Bupivacaine injection 0.5% (DrugBank: Bupivacaine)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 168 | エーラス・ダンロス症候群 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04036305 (ClinicalTrials.gov) | July 26, 2019 | 25/7/2019 | Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers | Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers | Ehlers-Danlos Syndrome;Anesthesia, Local | Drug: 0.9% Sodium Chloride Injection;Drug: Lidocaine Injection 2%;Drug: Bupivacaine Injection 0.5% | Vanderbilt University Medical Center | University of Calgary | Enrolling by invitation | 18 Years | N/A | All | 230 | United States |